Drug Information

Drug General Information
Drug ID
D0S6CW
Former ID
DIB021166
Drug Name
VPC32183
Synonyms
compound 10t [PMID: 15125924]
Drug Type
Small molecular drug
Indication Discovery agent Investigative [527065]
Structure
Download
2D MOL
Formula
C33H51N2O6P
InChI
InChI=1S/C33H51N2O6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-19-33(36)35-31(28-41-42(37,38)39)25-29-20-22-32(23-21-29)40-27-30-18-17-24-34-26-30/h9-10,17-18,20-24,26,31H,2-8,11-16,19,25,27-28H2,1H3,(H,35,36)(H2,37,38,39)/b10-9-/t31-/m1/s1
InChIKey
KMTDWYLEJRZIJN-HWNQJZBBSA-N
PubChem Compound ID
44392752
PubChem Substance ID
103448441, 104038573, 135651309
Target and Pathway
Target(s) Lysophosphatidate-3 receptor Target Info Antagonist [527065]
Lysophosphatidic acid receptor Edg-2 Target Info Antagonist [527065]
KEGG Pathway Rap1 signaling pathway
Neuroactive ligand-receptor interaction
PI3K-Akt signaling pathway
Pathways in cancerhsa04015:Rap1 signaling pathway
Gap junction
Pathways in cancer
NetPath Pathway TGF_beta_Receptor Signaling Pathway
Pathway Interaction Database LPA receptor mediated eventslysophospholipid_pathway:LPA receptor mediated events
Reactome G alpha (q) signalling events
G alpha (i) signalling events
Lysosphingolipid and LPA receptorsR-HSA-416476:G alpha (q) signalling events
Lysosphingolipid and LPA receptors
WikiPathways Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signalingWP289:Myometrial Relaxation and Contraction Pathways
Small Ligand GPCRs
GPCR downstream signaling
References
Ref 527065Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2735-40.
Ref 527065Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2735-40.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.